logo
Watch These Amazon Stock Price Levels After Post-Earnings Tumble

Watch These Amazon Stock Price Levels After Post-Earnings Tumble

Yahoo2 days ago
Key Takeaways
Amazon shares are in focus to start the week after plunging Friday as quarterly results from the e-commerce and cloud provider failed to impress investors.
The stock price fell below the lower trendline of a rising wedge pattern on Friday, potentially laying the groundwork for further earnings-related selling.
Investors should watch key support levels on Amazon's chart around $199, $190 and $175, while also monitoring a major overhead area near $233.Amazon (AMZN) shares are in focus to start the week after plunging Friday as quarterly results from the e-commerce and cloud provider failed to impress investors.
While the company posted growth in its Amazon Web Services business, investors may have expected more after rivals Microsoft (MSFT) and Google parent Alphabet (GOOGL) recently reported strong results in their cloud units. The company's AWS revenue grew 17.5% in its latest quarter, well below Microsoft's Azure growth of 39% and trailing the 32% sales increase in Google Cloud Platform. Following the results, analysts at Jefferies said that AWS growth was 'disappointing given big momentum at Azure and GPC.'
Amazon shares fell 8% to just close Friday's session at just below $215, pushing the stock into negative territory for the year. Some analysts raised their price targets on Amazon following the earnings report, with those at JPMorgan analysts saying they 'would buy the pullback.'
Below, we take a closer look at Amazon's chart and apply technical analysis to point out key post-earnings price levels that investors will likely be watching.
Rising Wedge Breakdown
Since setting their early-April low, Amazon shares had trended higher within a rising wedge, a move that coincided with the 50-day moving average (MA) recently crossing above the 200-day MA to form a bullish golden cross.
However, the stock's upward momentum ended abruptly Friday, with the price closing below the rising wedge pattern's lower trendline, potentially laying the groundwork for further selling.
Let's identify key support levels on Amazon's chart to watch and also point out a major overhead area worth monitoring during potential recovery efforts.
Key Support Levels to Watch
The first support level to watch sits around $199. The shares may find support in this location near last July's peak, which also closely aligns with troughs that formed on the chart in November and May.
A decisive close below this level could see the stock revisit support at $190. Investors may look to accumulate shares in this region around a multi-month horizontal line that connects a range of corresponding price action on the chart extending back to April last year.
A deeper retracement opens the door for the shares revisiting lower support at the $175 level. This area could attract buying interest near a series of trading activity on the chart stretching from February last year to April this year.
Major Overhead Area Worth Monitoring
During potential recovery efforts in Amazon's stock, it's worth monitoring how the price responds to the $233 level. This area on the chart could provide selling pressure near the rising wedge pattern's peak and the December swing high.
The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info.
As of the date this article was written, the author does not own any of the above securities.
Read the original article on Investopedia
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Philip Morris Stock Outlook: Is Wall Street Bullish or Bearish?
Philip Morris Stock Outlook: Is Wall Street Bullish or Bearish?

Yahoo

time12 minutes ago

  • Yahoo

Philip Morris Stock Outlook: Is Wall Street Bullish or Bearish?

With a market cap of $253.7 billion, Philip Morris International Inc. (PM) is a global tobacco company focused on delivering a smoke-free future. Its product portfolio includes traditional cigarettes, smoke-free alternatives like IQOS and ZYN, and expanding offerings in wellness and healthcare. Shares of the Stamford, Connecticut-based company have outperformed the broader market over the past 52 weeks. PM stock has surged 38.3% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.4%. Moreover, shares of Philip Morris are up 35.4% on a YTD basis, compared to SPX's 7.6% increase. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, the tobacco giant stock has also outpaced the Consumer Staples Select Sector SPDR Fund's (XLP) 1.6% rise over the past 52 weeks. Despite reporting a better-than-expected Q2 2025 adjusted EPS of $1.91, shares of Philip Morris tumbled 8.4% on Jul. 22. Total sales rose 7.1% to $10.1 billion and ZYN shipments came in at 190 million cans, both missing analysts' estimates. For the fiscal year ending in December 2025, analysts expect PM's adjusted EPS to grow 14.3% year-over-year to $7.51. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters. Among the 14 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on nine 'Strong Buy' ratings, two 'Moderate Buys,' and three 'Holds.' On Jul. 14, UBS maintained its 'Neutral' rating on Philip Morris but raised its price target to $181, citing strong smoke-free margin growth driven by IQOS and ZYN, with robust U.S. volume projections and revised earnings estimates through 2027. As of writing, the stock is trading below the mean price target of $193.38. The Street-high price target of $220 implies a potential upside of nearly 35% from the current price. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

Yahoo

time12 minutes ago

  • Yahoo

Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Finance and foreign ministers in Mexico to talk trade ahead of Carney's visit
Finance and foreign ministers in Mexico to talk trade ahead of Carney's visit

Yahoo

time12 minutes ago

  • Yahoo

Finance and foreign ministers in Mexico to talk trade ahead of Carney's visit

OTTAWA — Foreign Affairs Minister Anita Anand and Finance Minister François-Philippe Champagne are in Mexico to meet with President Claudia Sheinbaum to talk economic growth, trade and security. Their trip is happening ahead of Prime Minister Mark Carney's planned visit to Mexico to meet with Sheinbaum. The U.S. hit Canada on Friday with a 35 per cent tariff on goods not compliant with the Canada-United States-Mexico agreement on trade, known as CUSMA, while Mexico received a 90-day reprieve from threatened higher levies. CUSMA is scheduled for a mandatory review next year. Ontario Premier Doug Ford called last year for a bilateral trade deal between Canada and the United States because he said Mexico was serving as a back door for Chinese auto parts and vehicles entering the North American market. Anand and Champagne will also meet with Canadian and Mexican business leaders during the two-day trip. This report by The Canadian Press was first published Aug. 5, 2025. David Baxter, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store